why am i not losing weight fast on tirzepatide Zepbound: Common Causes Retatrutide vs Tirzepatide (2026): Differences

in adults, it is associated with neurological disorders including cognitive decline, depression, and neuropathy, as well as Alzheimer and Parkinson diseases

For people with type 2 diabetes or obesity, it may also lower the risk of cardiovascular complications.

[18] Access considerations are important for patients to understand: Referral to Tier 3 or 4 specialist weight management services is required for NHS-funded weight management treatment with GLP-1 agonists Local formularies may restrict which GLP-1 agonists are available Supply shortages have affected availability, particularly for higher-dose formulations Private prescriptions may be necessary for those not meeting NHS criteria Ongoing monitoring and specialist input are typically required Patients interested in GLP-1 agonist therapy should discuss their individual circumstances with their GP, who can advise on local referral pathways to specialist services if appropriate

Catherine Varney, obesity medicine director for UVA Health in Charlottesville, Va., says she has about 1,000 patients on obesity drugs